The transaction, which officially closed on July 23, 2026, was facilitated by FT Global Capital, Inc. acting as the exclusive placement agent. The shares were issued under a shelf registration statement originally filed with the U.S. Securities and Exchange Commission in early 2024.

China Pharma Holdings operates as a specialty pharmaceutical firm focused on high-mortality conditions such as cardiovascular and infectious diseases. With its manufacturing hub centered in Hainan Province through its subsidiary, Hainan Helpson Medical & Biotechnology, the company maintains eight GMP-certified production lines intended to serve its broad distribution network across China.